Skip to main content
RESMED INC logo

RESMED INC — Investor Relations & Filings

Ticker · RMD LEI · 254900O2VD7IQ5OGI615 ASX Manufacturing
Open in API
Filings indexed 1,643 across all filing types
Latest filing 2007-09-10 Director's Dealing
Country AU Australia
Listing ASX RMD

About RESMED INC

https://www.resmed.com

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s primary product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel machines, and a variety of masks and accessories designed to improve patient adherence and comfort. ResMed distinguishes itself through its focus on digital health, offering integrated software platforms that enable remote patient monitoring and data-driven clinical insights for healthcare providers. Additionally, the company provides software-as-a-service (SaaS) solutions to support out-of-hospital care settings, including home health, hospice, and skilled nursing facilities, aiming to improve patient outcomes and reduce overall healthcare costs.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about a director's transactions in company securities, including shares disposed, dates, and values. It references ASX listing rules and the Corporations Act, indicating it is a regulatory filing related to insider trading or director share dealings. The content is specific to a director's personal share transactions and does not include financial results, management discussion, or other report types. The document length is 2876 characters, which is typical for such notices. Therefore, this document fits the category of Director's Dealing (DIRS).
2007-09-10 English
ResMed Names Kieran Gallahue as Chief Executive Officer.. 1
Board/Management Information Classification · 100% confidence The document is an announcement regarding a change in the company's executive management, specifically naming a new Chief Executive Officer and describing the succession plan. It does not contain financial data, regulatory filings, or report publications. The content focuses on board and management changes, which aligns with the category for announcements about changes in the company's board of directors or senior management.
2007-08-30 English
Appendix 4E and Form 10-K 117 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E Preliminary final report' and includes detailed consolidated financial statements such as the Statement of Financial Performance, Statement of Financial Position, and Statement of Cash Flows for the fiscal year ended June 30, 2007. It references the Form 10-K for the year ended June 30, 2007 multiple times, indicating that this document is the official annual report. The presence of comprehensive financial data, notes, and management commentary aligns with the characteristics of an Annual Report (10-K). The document is lengthy (15,000 characters) and contains substantive financial information, not merely an announcement or certification. Therefore, the correct classification is Annual Report (10-K). FY 2007
2007-08-28 English
Daily Share Buy-Back Notice - Appendix 3E 2 pages ?Kb
Transaction in Own Shares Classification · 100% confidence The document is titled 'Daily share buy-back notice' and references Appendix 3E, which is a regulatory form related to share buy-back disclosures. It provides detailed information about the number of shares bought back, prices paid, and compliance statements. The document is relatively short (2322 characters) and focuses on reporting a share repurchase activity rather than a full financial report or earnings release. It is not an announcement of a report publication but a direct disclosure of a transaction in own shares. Therefore, the document fits the category of 'Transaction in Own Shares' (POS).
2007-08-21 English
Daily share buy-back notice - Appendix 3E 2 pages ?Kb
Transaction in Own Shares Classification · 100% confidence The document is titled 'Daily share buy-back notice' and references Appendix 3E, which is a standard form used for reporting share buy-back activities to the ASX (Australian Securities Exchange). It contains detailed information about the number of shares bought back, total consideration paid, highest and lowest prices paid, and compliance statements. The document is a notice about the company's share repurchase activity rather than a full financial report or earnings release. It does not contain financial statements or management discussion but focuses solely on the share buy-back transaction. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and specific to buy-back details, confirming this classification with high confidence.
2007-08-20 English
Daily Share Buy-Back Notice 2 pages ?Kb
Transaction in Own Shares Classification · 100% confidence The document is titled 'Daily share buy-back notice' and references Appendix 3E, which is a standard form for reporting on-market share buy-back activities to the ASX (Australian Securities Exchange). It contains detailed information about the number of shares bought back, prices paid, and compliance statements. The document is short (2268 characters) and focuses solely on share repurchase activity, with no financial statements or broader financial performance data. This matches the definition of a 'Transaction in Own Shares' filing, which reports on company buybacks or sales of its own shares. Therefore, the correct classification is POS (Transaction in Own Shares).
2007-08-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.